GLPwatch
Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy
NCT02843399 · Completed
Last updated 2026-05-28This clinical trial compares the economic impact of once-weekly exenatide (EQW) versus daily insulin glargine (IG) in adults with type 2 diabetes who are starting injectable therapy for the first time.
Status Completed The study has finished.
Type Observational
Participants 15,498 people
Who can join Ages 18–99 · all sexes
Timeline Started 2016-08 · est. completion 2016-12
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT02843399 ↗
Description as written by the study sponsor.
Primary objective of this study is to compare diabetes-related healthcare utilization and costs in patients initiating exenatide once weekly vs insulin glargine.
| Main thing measured | Diabetes-related HCRU/costs |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Diabetes Mellitus Type 2 |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02843399 ↗